Geno NIPT 23 Plus
Screens all 23 fetal chromosome pairs and 21 common maternal recessive genetic conditions.
Screens all 23 fetal chromosome pairs and 21 common maternal recessive genetic conditions.
NIPT is a screening test, not a diagnostic test. Please seek professional advice about eligibility and the meaning of your result.
Understanding NIPT screening
NIPT analyzes cell-free DNA in maternal blood, including DNA originating from the placenta, to assess the chance of selected fetal chromosome conditions. It uses a maternal blood sample without directly sampling the fetus. Packages differ in scope; choose after counseling, not simply by the number of items.
Package screening scope
All 23 chromosome pairs
21 recessive genetic conditions
What do these items mean?
All 23 chromosome pairs
Extends chromosome-number screening to the 22 autosomal pairs and the sex chromosome pair. “23 pairs” describes screening scope; it does not mean diagnosis of every genetic disease or structural chromosome change.
21 recessive genetic conditions
Adds maternal carrier screening for 21 conditions in the package panel, including conditions such as Thalassemia, G6PD deficiency, phenylketonuria, Wilson disease and spinal muscular atrophy. It does not replace fetal diagnosis; confirm the exact gene panel and seek counseling if a variant is reported.
From blood sample to result counseling
Counseling & maternal blood sample
Confirm gestational age, history and package suitability with your clinician before sampling.
DNA analysis
The laboratory analyzes the sample within the chosen panel. Result turnaround: 2–4 days.
Results & follow-up counseling
Your clinician explains the risk, the result’s limitations and any follow-up needed.
Results & important limitations
Low risk
Makes the screened conditions less likely but does not exclude them. Continue recommended prenatal care and ultrasound; NIPT does not assess every genetic condition or birth defect.
High risk
Does not diagnose an affected fetus. Seek genetic counseling and discuss diagnostic testing such as chorionic villus sampling or amniocentesis before important medical decisions.
No result / nonreportable result
Does not mean low risk. Your clinician will assess whether repeat sampling, ultrasound or diagnostic testing is appropriate.
Included tests
| Test name | Code | TAT |
|---|---|---|
| Geno NIPT 23 Plus non-invasive prenatal screening | — | 2–4 days |